Know Cancer

or
forgot password

ROR1 as a Novel Target for Neuroblastoma


N/A
N/A
N/A
Open (Enrolling)
Both
Neuroblastoma

Thank you

Trial Information

ROR1 as a Novel Target for Neuroblastoma


OBJECTIVES:

Primary

- To analyze the expression of ROR1 on the surface of primary neuroblastoma cells.

- To investigate the therapeutic potential of anti-ROR1 monoclonal antibodies (mAbs),
bispecific antibodies, and immunotoxins in in vitro and in vivo models of
neuroblastoma.

OUTLINE: Archived bone marrow and tumor tissue samples are analyzed for ROR1 expression by
flow cytometry, western blotting, qPCR, and IHC.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Diagnosed with neuroblastoma

- With or without N-myc amplification

- Primary tumor samples as frozen tissue in liquid nitrogen or -80 degrees C

- Bone marrow samples from high-risk patients as peripheral blood mononuclear cells
(PBMC) that have been cryopreserved with DMSO as viable cells to be used for flow
cytometry or slides of bone marrow that can be used for immunohistochemistry

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Not specified

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

ROR1 is expressed on the surface of neuroblastoma cells and constitutes a suitable target for mAb therapy

Safety Issue:

No

Principal Investigator

David Hema, MD, MPH

Investigator Role:

Principal Investigator

Investigator Affiliation:

NCI - Experimental Transplantation and Immunology Branch

Authority:

United States: Federal Government

Study ID:

CDR0000700607

NCT ID:

NCT01358604

Start Date:

May 2011

Completion Date:

Related Keywords:

  • Neuroblastoma
  • localized resectable neuroblastoma
  • recurrent neuroblastoma
  • regional neuroblastoma
  • stage 4S neuroblastoma
  • localized unresectable neuroblastoma
  • Neuroblastoma

Name

Location